Roche Palo Alto LLC

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Ryan Craig Schoenfeld

Robert James Weikert

Matthew C Lucas

Francisco Xavier Talamas

Jim W Li

Javier De Vicente Fidalgo

Pravin Iyer

Stephen Matthew Lynch

Clara Jeou Jen Lin

David Scott Carter

Marzia Villa

Achyutharao Sidduri

Peter Michael Wovkulich

Elbert Chin

Shu-Hai Zhao

Weiya Yun

Johannes Cornelius Hermann

Adrian Wai-Hing Cheung

Ann Marie Madera

Joshua Jahmil Kennedy-Smith

Fernando Padilla

Joshua Paul Gergely Taygerly

Eun Kyung Lee

Kerem Erol Ozboya

Yimin Qian

Eric Brian Sjogren

Michael Patrick Dillon

Matthew Michael Hamilton

Ce Wang

Counde O'Yang

Kin-Chun Thomas Luk

Michael Soth

Kenneth Albert Brameld

Allen John Lovey

Shaoqing Chen

Christine E Brotherton-Pleiss

Hongju Li

Leanna Staben

Xiaohu Zhang

Alfred Sui-Ting Lui

Joshua Kennedy-Smith

Kristen Lynn McCaleb

Yansheng Zhai

Sandra Steiner

David Budd

Counde O'yang

Shelley K Gleason

Javier De Vincente Fidalgo

Stephen M Lynch

Jim Li

Leanna Renee Staben

The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Antiviral compounds

The present invention relates to the use of novel pyrrolo[2,3-b]]pyrazines wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases. 

Pyrrolo[2,3-B]pyrazines as SYK inhibitors

Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such pulmonary fibrosis. 

LPAR&#x2014;substituted cyanopyrazole compounds

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Pyrrolopyrazine kinase inhibitors

Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof

Method for treating an HCV infection and inhibiting HCV replication with a compound of formula I wherein R, R, R, R, X, X, Xand Xand as defined herein 

Quinoline inhibitors of hepatitis C virus polymerase

Compounds having the formula I wherein R, R, Rand X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. 

Heterocyclic antiviral compounds

Compounds of the formula: or pharmaceutically acceptable salts thereof,

Tetrahydroquinoline indole derivatives and uses thereof

Compounds having the formula I wherein R, R, R, R, R, R, R, R, Rand n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. 

This application discloses compounds of generic Formula I: or pharmaceutically acceptable salts thereof, wherein A, R, R, R, R, Q, X, Y, m, p, and q are defined as described herein, useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

Substituted indolyl and indazolyl derivatives and uses thereof

Compounds having the formula I wherein A, R, R, R, R, R, R, R, R, R, R, Ar, R, R, R, R, X, n and p are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. 

Compounds having the formula I wherein R, R, R, R, R, R, Rand Rare as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. 

Compounds having the formula I wherein R, R, R, R, and Rare as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. 

This application discloses aminopiperidinyl compounds of generic Formulae I-II: or pharmaceutically acceptable salts thereof, wherein m, r, Q, Q, Q, R, R, R, R, R, and Rare defined as described herein, useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

Aminopiperidinyl derivatives and uses thereof

Growing community of inventors

San Jose, CA, United States of America

Ryan Craig Schoenfeld